NCT06300528View on ClinicalTrials.gov

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

December 31, 2030

Conditions
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Interventions
DRUG

Pemigatinib

Pemigatinib will be self-administered as a once-a-day oral treatment on a 28-day cycle.

Trial Locations (1)

84112

RECRUITING

Huntsman Cancer Institute at University of Utah, Salt Lake City

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

University of Utah

OTHER